New research published this month in Mucosal Immunology finds that cannabidiol (CBD) may interfere with multiple early-stage processes involved in HIV transmission, including direct infection of key immune cells and viral transfer within mucosal tissue.
The study, conducted by researchers from Université Paris Cité, focused on how HIV-1 spreads through mucosal surfaces, where the virus typically first encounters the body. These tissues contain immune cells such as CD4+ T-cells, macrophages, Langerhans cells, and dendritic cells, all of which can play a role in establishing infection.
Researchers found that CBD activates a receptor known as TRPV1, which in turn triggers the release of a neuropeptide called calcitonin gene-related peptide (CGRP). This signaling pathway appears to significantly reduce HIV’s ability to infect immune cells.
In lab settings, CBD was shown to directly inhibit HIV infection in macrophages and CD4+ T-cells. It also reduced the ability of Langerhans cells and dendritic cells to transfer the virus to T-cells, a key step in the spread of infection after initial exposure.
Importantly, the study extended beyond isolated cells. Using human inner foreskin tissue samples, researchers found that CBD disrupted early transmission events, including the formation of cell-to-cell interactions that allow HIV to spread. This suggests the compound may be effective at blocking infection at one of its earliest stages.
The findings indicate that CBD acts across multiple pathways involved in HIV transmission, rather than targeting a single mechanism. Researchers say this broad activity raises the possibility of using CBD-based products as a form of pre-exposure prophylaxis, sometimes referred to as “CBD PrEP.”
While the results are based on laboratory and ex vivo models, they point to a potentially new role for CBD in HIV prevention, warranting further clinical research.
